Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343564
Status:
COMPLETED
Last Update Posted:
2020-01-13
First Post:
2006-06-21
Brief Title:
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Sponsor:
Cytokinetics
Organization:
Cytokinetics
Study Overview
Official Title:
A Phase I-II Study to Determine the Safety Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was an early-phase trial arranged into two phases The Phase I portion was a dose-escalation study designed to assess the safety tolerability and to identify the maximum tolerated dose of SB-743921 in patients with Non-Hodgkin Lymphoma and Hodgkin Lymphoma Phase II was intended to assess the activity safety and tolerability of SB-743921 in patients with Indolent and Aggressive Non-Hodgkins Lymphomas exclusively The Phase II portion of the study was not initiated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None